GALDERMA
Galderma today announced top-line results from a Phase 2 study on the impact of dose escalation on the duration of effect and the efficacy and safety of a single dose of Dysport ® (abobotulinumtoxinA) for Injection (50U, 75U, 100U or 125U) versus placebo for the treatment of moderate to severe frown lines between the eyebrows (glabellar lines). Results showed that the study met its primary endpoint, with significantly more subjects treated with Dysport ® at all four doses achieving a composite two grade improvement responder rate than those treated with placebo at one month. Data from secondary endpoints demonstrated promising results for a potential prolonged duration of effect correlated with higher doses. Dysport ® , also marketed as Azzalure® in some countries, is a prescription injection for temporary improvement in the look of moderate to severe glabellar lines in adults less than 65 years of age.
“We are encouraged that these study results demonstrate that a single dose of Dysport ® has a rapid onset, long-lasting effect and is well tolerated,” said John H. Joseph, M.D., investigator for the study and director of The Clinical Testing Center of Beverly Hills. “At all doses tested in the trial, Dysport ® had a strong safety profile, including very few cases of eyelid ptosis.”
Phase 2 Dose-Escalating Study Design and Results
The multicenter, randomized, dose-ranging, double-blind, placebo-controlled Phase 2 study enrolled 401 subjects ages 18 to 65 with moderate to severe glabellar lines at maximum frown. Study participants were randomized 4:1 to receive a single dose of Dysport
®
(50U, the dose in the FDA-approved label, 75U, 100U or 125U) or placebo and followed for nine months. The primary objective of the study was to evaluate the efficacy of a single dose of Dysport
®
as assessed by the composite responder rate at maximum frown at one month. Secondary objectives evaluated other measures of efficacy as well as duration of treatment response, subject satisfaction, aesthetic improvement and onset of treatment response.
Top-line efficacy results showed that the study met its primary endpoint. After one month, all dose groups treated with Dysport ® showed a statistically significant composite (investigator and subject-assessed) ≥2-grade improvement when compared with placebo. Favorable results were achieved for all doses in the secondary objectives, including a ≥1-grade improvement and subject satisfaction throughout the study duration. Dysport ® was well tolerated with a similar safety profile across all doses tested. Treatment-related adverse events were mild or moderate in severity and transient, and no treatment-related serious adverse events were reported.
“This phase 2 study underscores our commitment to bring efficacious products and long-lasting results to customers,” said Baldo Scassellati Sforzolini, Global Head of Research & Development at Galderma. “Based on these encouraging safety and long-term efficacy results, as well as continued patient satisfaction, we are evaluating future clinical studies.”
About Galderma's collaboration with Ipsen
Dysport
®
(abobotulinumtoxinA) is a prescription injection for temporary improvement in the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults less than 65 years of age. Dysport
is also marketed as Azzalure®
in the EU for the treatment of glabellar lines with more than 40 million treatments in the EU and U.S. combined and with approvals in 74 countries.
Dysport
®
is manufactured by Ipsen, a global specialty-driven pharmaceutical company. Since 2009, Galderma and Ipsen have had a strategic partnership under which Galderma has promoted and distributed Ipsen's botulinum toxin type A products in aesthetic indications. The Ipsen-Galderma strategic partnership now covers China, the United States, the European Union, Australia, South Korea, Canada, Brazil, Argentina, and certain other countries. Ipsen continues to promote Dysport
®
within certain therapeutic indications in countries around the world.
For more information on Ipsen, visit www.ipsen.com
.
About Galderma
Galderma, the world's largest independent global dermatology company, was created in 1981 and is now present in over 100 countries with an extensive product portfolio of prescription medicines, aesthetic solutions and consumer care products. The company partners with health care practitioners around the world to meet the skin health needs of people throughout their lifetime. Galderma is a leader in research and development of scientifically-defined and medically-proven solutions for the skin. For more information, please visit www.galderma.com/
.
# # #
Visit www.fda.gov/medwatch or call 1‐800‐FDA‐1088.
For U.S. audiences please see Dysport Full Prescribing Information including Medication Guide at DysportUSA.com .
The Dysport trademark is used under license. All trademarks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201117005773/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
DANA, Indonesia's E-Wallet Leader, and Ant International Launch Digital Sustainability InitiativeSupported by Konservasi Indonesia for Marine Conservation10.10.2025 07:24:00 CEST | Press release
Ocean Buddy, an interactive app-based mini-program inspired by Ant Forest, leverages digital technology to support marine conservation and the protection of whale sharks in Indonesia.Project underlines DANA's ESG vision for building community-wide climate resilience, and Ant International's new Sustainability Framework focused on innovation and collaboration for inclusive, sustainable growth. DANA and Ant International, together with Konservasi International, today unveiled the Ocean Buddy initiative, an interactive in-app mini program to raise awareness and drive long-term public participation in marine conservation among DANA's 200 million users in Indonesia. The launch was announced at the International Union for Conservation of Nature (IUCN) World Conservation Congress 2025 in Abu Dhabi. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251009459552/en/ From left to right: Ms Sabrina Peng, Senior Vice President, Chief Susta
Megaport Cloud Network Report 2025: The State of Cloud Networking10.10.2025 00:42:00 CEST | Press release
Megaport releases new global insights revealing how enterprises are orchestrating networks to deliver performance, compliance, and resilience at scale. Megaport Limited (Megaport) (ASX: MP1), the global leader in Network as a Service (NaaS), today released its 2025 Cloud Network Report, revealing a decisive industry shift: enterprises are going further than expansion and growth with connectivity and are virtualizing and orchestrating their networks to deliver resilience, sovereignty, and performance at scale. The report draws on operational data from Megaport’s platform, spanning over 1,000 enabled locations across 150+ cities, and global survey insights from IT leaders. Findings show that routing and edge product deployments grew 42% year-on-year, underscoring a move from static cloud builds to programmable, intelligent fabrics. “The future of competitiveness lies in how well enterprises can virtualize and orchestrate connectivity. Intelligent routing, segmentation, and traffic shapin
Registration Continues for the Second Edition of “Miyahthon” to Advance Innovation in Water Sustainability9.10.2025 22:11:00 CEST | Press release
The Saudi Water Authority is continuing to accept applications for participation in the second edition of the global hackathon “Miyahthon”, which brings together innovators and entrepreneurs from Saudi Arabia and beyond to develop sustainable solutions for the future of water. Registration remains open until 11 October 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251009024083/en/ Registration Continues for the Second Edition of “Miyahthon” to Advance Innovation in Water Sustainability (Photo: AETOSWire) This edition builds on the success of the inaugural Miyahthon, which witnessed wide participation from both local and international innovators. It led to the development of groundbreaking projects, including the “Smart Ric” water treatment solution and “Hydraya”, an artificial intelligence application. The winning projects were incubated in the business accelerators of the Saudi Water Innovation Center, enabling them
Vantiva Accelerates Net-Zero Commitment to 2040 with SBTi-Approved Targets9.10.2025 18:43:00 CEST | Press release
Vantiva (Euronext Paris: VANTI), a global technology leader in connectivity, today announced that the Science Based Targets initiative (SBTi) has approved the company's near- and long-term science-based targets, confirming that Vantiva's targets align with the latest climate science and the 1.5°C ambition of the Paris Agreement. The SBTi's approval of Vantiva's science-based targets demonstrates the company's commitment to measurable decarbonization. Vantiva's targets with a 2021 base year include: By 2030: Reduce absolute Scope 1 and 2 GHG emissions by 80.0%, absolute Scope 3 GHG emissions from the use of sold products by 60.0%, and overall absolute Scope 3 GHG emissions by 55.0%. By 2040 (Net-zero target): Reduce absolute Scope 1 and 2 GHG emissions by 90.0% and absolute Scope 3 GHG emissions by 90.0%. This accelerates Vantiva's net-zero goal ten years from its previously set 2050 target. Continuing its 30-year legacy of responsible business practices, Vantiva will focus on direct em
ARIA Commodities Announces US$135 Million Reverse Takeover of London listed Kibo Energy, by Carbon Resilience, a 14GW Australian Renewable Energy Platform9.10.2025 18:01:00 CEST | Press release
The institutional asset management platform of ARIA Commodities’ group today announced a reverse takeover (RTO) transaction with Kibo Energy PLC (AIM: KIBO; AltX: KBO), the dual-listed energy development company. The US$135 million acquisition, transacted in concert with ARIA’s group institutional asset management business, will be satisfied through the issuance of approximately 966 million new Kibo shares at a deemed price of £0.104 per share, following a proposed 1,600-to-1 share consolidation. The transaction marks a significant reverse takeover (RTO) under AIM Rule 14 and represents Kibo’s strategic pivot toward large-scale, global industrial decarbonisation. A Portfolio with Global Potential Carbon Resilience controls a portfolio of eight strategically located renewable energy sites across Queensland, spanning more than 900,000 hectares and offering a potential generation capacity exceeding 14 gigawatts (GW). The projects combine onshore wind, solar PV and battery energy storage s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom